1431507-79-7

Basic information

• Product Name: [(2R, 5R)-2-(hydroxymethyl)-5-methylthiomorpholin-4-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
• Synonyms: [(2R, 5R)-2-(hydroxymethyl)-5-methylthiomorpholin-4-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
• CAS NO: 1431507-79-7
• Molecular Weight: 332.426
• Mol File: 1431507-79-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [(2R, 5R)-2-(hydroxymethyl)-5-methylthiomorpholin-4-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone(CAS DataBase Reference)
• NIST Chemistry Reference: [(2R, 5R)-2-(hydroxymethyl)-5-methylthiomorpholin-4-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone(1431507-79-7)
• EPA Substance Registry System: [(2R, 5R)-2-(hydroxymethyl)-5-methylthiomorpholin-4-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone(1431507-79-7)

Safety Data

• Hazardous Substances Data: 1431507-79-7(Hazardous Substances Data)

Upstream product

• 1431507-84-4 (2S,5R)-2-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-methylthiomorpholin-3-one 
• 1431507-77-5 (2R,5R)-2-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-methylthiomorpholine 
• 956317-36-5 2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoic acid 
• 52548-14-8 2-iodoyl-5-methylbenzoic acid 
• 1104546-96-4 5-methyl-2-(2Η-1,2,3-triazol-2-yl)benzoyl chloride 
• 1431507-78-6 [(2R, 5R)-5-methylthiomorpholin-2-yl]methanol 
• 1431507-83-3 (2S,5R)-2-(hydroxymethyl)-5-methylthiomorpholin-3-one 
• 1431507-82-2 methyl (2R,5R)-5-methyl-3-oxothiomorpholine-2-carboxylate 
• 1431507-81-1 dimethyl ({(2R)-2-[(tert-butoxycarbonyl)amino]propyl}sulfanyl)propanedioate 

Downstream Products

• 1431507-60-6 [(2R,5R)-2-{[(5-fluoropyridin-2-yl)oxy]methyl}-5-methylthiomorpholin-4-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone 

Relevant articles and documents

2,5-DISUBSTITUTED THIOMORPHOLINE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 2,5-disubstituted thiomorpholine amide compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2,5-disubstituted thiomorpholine amide compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.